Cilgavimab (Genetical Recombination)



Cilgavimab is a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody derived from human IgG1. In the H-chain, amino acid residues at positions 248, 249, 266, 268, 270 and 345 are substituted by Phe, Glu, Tyr, Thr, Glu and Ser, respectively. Cilgavimab is produced in Chinese hamster ovary cells. Cilgavimab is a glycoprotein (molecular weight: ca. 152,000) composed of 2 H-chains (γ1-chains) consisting of 461 amino acid residues each and 2 L-chains (κ-chains) consisting of 219 amino acid residues each.

[2420563-99-9]